Literature DB >> 7710946

Interleukin 1 modulates growth of human renal carcinoma cells in vitro.

I Koch1, H Depenbrock, S Danhauser-Riedl, J W Rastetter, A R Hanauske.   

Abstract

We have investigated the influence of interleukin 1 (IL-1) on growth of human renal carcinoma cells in vitro. Using a capillary soft-agar cloning system, 18% of freshly explanted renal carcinomas were stimulated to grow by IL-1 and 4% were inhibited. Subsequent experiments with established renal cancer cell lines demonstrated that two out of four cell lines (Caki-2, A-498) were sensitive to IL-1. [3H]Thymidine incorporation as well as monolayer growth was enhanced in Caki-2 cells in the presence of high (10%) and low (1%) serum concentrations. Although clonogenic growth of A-498 cells was stimulated by IL-1, overall [3H]thymidine incorporation and monolayer proliferation were decreased. Using radioligand experiments, 250 cell-surface receptors of high affinity (KD 4.5 x 10(-11) M) and 2500 receptors of low affinity (KD 1.3 x 10(-9) M) were detected on A-498 cells. IL-1 binding was reduced under the influence of IL-1. Competition experiments with inhibiting antibodies against IL-1 receptor type I and type II revealed that signal transduction was performed via type I receptors. After cross-linking to IL-1, receptor type I was immunoprecipitated using anti-IL-1 antibodies. We hypothesise that, since IL-1 modulates in vitro growth of a subgroup of human renal cancer cells, interference with its mechanism of action may be of potential value in order to modulate tumour proliferation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7710946      PMCID: PMC2033760          DOI: 10.1038/bjc.1995.154

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

Review 1.  Cytokines as positive and negative regulators of tumor promotion and progression.

Authors:  D F Michiel; J J Oppenheim
Journal:  Semin Cancer Biol       Date:  1992-02       Impact factor: 15.707

2.  Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice.

Authors:  R Giavazzi; A Garofalo; M R Bani; M Abbate; P Ghezzi; D Boraschi; A Mantovani; E Dejana
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Identification and distribution of two forms of the interleukin 1 receptor.

Authors:  R Solari
Journal:  Cytokine       Date:  1990-01       Impact factor: 3.861

5.  Interleukin 1 signaling occurs exclusively via the type I receptor.

Authors:  J E Sims; M A Gayle; J L Slack; M R Alderson; T A Bird; J G Giri; F Colotta; F Re; A Mantovani; K Shanebeck
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

6.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4.

Authors:  F Colotta; F Re; M Muzio; R Bertini; N Polentarutti; M Sironi; J G Giri; S K Dower; J E Sims; A Mantovani
Journal:  Science       Date:  1993-07-23       Impact factor: 47.728

7.  Interleukin-1 down-regulates gene and surface expression of interleukin-1 receptor type I by destabilizing its mRNA whereas interleukin-2 increases its expression.

Authors:  K Ye; K C Koch; B D Clark; C A Dinarello
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

8.  Interleukin 1 augments the expression of the interleukin 2 receptor alpha-chain in interleukin 6-stimulated myeloid cells by a transcriptional and posttranscriptional mechanism.

Authors:  S Ruhl; M Schwabe; D H Pluznik
Journal:  Exp Hematol       Date:  1992-11       Impact factor: 3.084

9.  Autocrine stimulation of interleukin-1 in the growth of human thyroid carcinoma cell line NIM 1.

Authors:  K Zeki; Y Nakano; N Inokuchi; K Watanabe; I Morimoto; U Yamashita; S Eto
Journal:  J Clin Endocrinol Metab       Date:  1993-01       Impact factor: 5.958

10.  Independent binding of interleukin-1 alpha and interleukin-1 beta to type I and type II interleukin-1 receptors.

Authors:  J Slack; C J McMahan; S Waugh; K Schooley; M K Spriggs; J E Sims; S K Dower
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

View more
  3 in total

1.  Antitumour and antiangiogenic activities of [Pt(O,O'-acac)(γ-acac)(DMS)] in a xenograft model of human renal cell carcinoma.

Authors:  A Muscella; C Vetrugno; F Biagioni; N Calabriso; M T Calierno; F Fornai; S A De Pascali; S Marsigliante; F P Fanizzi
Journal:  Br J Pharmacol       Date:  2016-07-22       Impact factor: 8.739

2.  5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma.

Authors:  Makito Miyake; Satoshi Anai; Kiyohide Fujimoto; Sayuri Ohnishi; Masaomi Kuwada; Yasushi Nakai; Takeshi Inoue; Atsushi Tomioka; Nobumichi Tanaka; Yoshihiko Hirao
Journal:  Oncol Lett       Date:  2012-03-29       Impact factor: 2.967

3.  Interleukin-1beta expression in human gastric carcinoma with Epstein-Barr virus infection.

Authors:  Ja-Mun Chong; Kazuya Sakuma; Makoto Sudo; Toshio Osawa; Etsuko Ohara; Hiroshi Uozaki; Junji Shibahara; Kenji Kuroiwa; Shin-Ichi Tominaga; Yoshitaka Hippo; Hiroyuki Aburatani; Nobuaki Funata; Masashi Fukayama
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.